Inebilizumab Injection bulk supplier for pharma manufacturers

Inebilizumab Injection 100 mg/10 mL Suppliers & Bulk Manufacturers

Available Forms: Concentrate vial (IV infusion)

Available Strengths: 100 mg/10 mL

Pack Sizes: Packs of 3 vials

Reference Brands: Uplizna (Amgen)

Inebilizumab (Uplizna, Amgen) is a CD19-targeted B-cell depleting antibody for NMOSD, IgG4-related disease and generalised myasthenia gravis. After two starting infusions it is given only twice a year. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Inebilizumab Injection? List it or send an offer →

Product Description:

Inebilizumab is a monoclonal antibody that binds CD19 on B cells and plasmablasts and removes them. CD19 is present on a wider range of antibody-producing cells than CD20, the target of rituximab and ocrelizumab, which helps explain its effect in diseases driven by autoantibodies.

It was first approved for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive, where it reduces relapses that can cause blindness and paralysis. In 2025 it became the first approved treatment for IgG4-related disease, and approval for generalised myasthenia gravis followed. The dose is 300 mg by intravenous infusion, repeated after two weeks and then every six months.

Sourcing notes. Inebilizumab is patented and there is no biosimilar. Each 300 mg dose uses three 100 mg vials, so orders are usually planned per patient per year. It is a cold-chain product. Ravulizumab and eculizumab, also used in NMOSD, are listed on PharmaTradz.

How Inebilizumab Injection is supplied today, and licensing ahead of patent expiry

Inebilizumab Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Inebilizumab Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Inebilizumab Injection supply →

Back to Listing